TAIPEI, May 16, 2025 /PRNewswire/ -- The broad-spectrum antiviral siRNA drug SNS812, co-developed by Oneness Biotech (4743.TW) and Microbio (Shanghai), has been selected for oral presentation at the prestigious 2025 American Thoracic Society (ATS) International Conference. The...
Hence then, the article about sns812 an innovative sirna drug from oneness and microbio shanghai selected for ats 2025 oral presentation demonstrating world leading clinical outcomes in covid 19 treatment was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( SNS812, an innovative siRNA drug from Oneness and Microbio (Shanghai), selected for ATS 2025 oral presentation, demonstrating world-leading clinical outcomes in COVID-19 treatment )
Also on site :
- 1968 Figure Skating Legend Won the Gold at 19 Years Old After Tragic Plane Crash Devastated Entire U.S. Team
- '90s One-Hit Wonder That Became a Worldwide Phenomenon Began a 14-Week Run at No. 1, 30 Years Ago Today
- Walmart's Vintage-Inspired Solar Lanterns Double as Planters, and You Can Snag a 2-Pack for Under $30